Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Celldex Therapeutics
NextCure, Inc.
University of Florida
Klus Pharma Inc.
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
AbbVie
AbbVie
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
FeRx